Genmab A/S (NASDAQ: GMAB) stock closed at 37.76 per share at the end of the most recent trading day (a 0.53% change compared to the prior day closing price) with a volume of 337.01K shares and market capitalization of 24.64B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 781 people. Genmab A/S CEO is Jan G. J. van de Winkel.

The one-year performance of Genmab A/S stock is 3.81%, while year-to-date (YTD) performance is -10.9%. GMAB stock has a five-year performance of %. Its 52-week range is between 26.19 and 47.5, which gives GMAB stock a 52-week price range ratio of 54.29%

Genmab A/S currently has a PE ratio of 36.30, a price-to-book (PB) ratio of 7.50, a price-to-sale (PS) ratio of 20.87, a price to cashflow ratio of 53.30, a PEG ratio of 2.32, a ROA of 20.68%, a ROC of 22.45% and a ROE of 23.59%. The company’s profit margin is 52.71%, its EBITDA margin is 61.40%, and its revenue ttm is $1.35 Billion , which makes it $2.05 revenue per share.

Of the last four earnings reports from Genmab A/S, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.13 for the next earnings report. Genmab A/S’s next earnings report date is 10th May 2023.

The consensus rating of Wall Street analysts for Genmab A/S is Hold (2.59), with a target price of $42.09, which is +11.47% compared to the current price. The earnings rating for Genmab A/S stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Genmab A/S has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Genmab A/S has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.77, ATR14 : 0.70, CCI20 : 114.83, Chaikin Money Flow : 0.00, MACD : -0.03, Money Flow Index : 73.40, ROC : 5.74, RSI : 55.61, STOCH (14,3) : 92.75, STOCH RSI : 0.91, UO : 58.50, Williams %R : -7.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Genmab A/S in the last 12-months were: